chr16-1229429-C-G
Position:
Variant summary
Our verdict is Likely benign. Variant got -2 ACMG points: 0P and 2B. BP4_Moderate
The NM_024164.6(TPSB2):āc.261G>Cā(p.Arg87Ser) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00182 in 1,183,002 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (ā ).
Frequency
Genomes: š 0.0018 ( 0 hom., cov: 9)
Exomes š: 0.0018 ( 0 hom. )
Failed GnomAD Quality Control
Consequence
TPSB2
NM_024164.6 missense
NM_024164.6 missense
Scores
6
7
Clinical Significance
Conservation
PhyloP100: 1.17
Genes affected
TPSB2 (HGNC:14120): (tryptase beta 2) Tryptases comprise a family of trypsin-like serine proteases, the peptidase family S1. Tryptases are enzymatically active only as heparin-stabilized tetramers, and they are resistant to all known endogenous proteinase inhibitors. Several tryptase genes are clustered on chromosome 16p13.3. These genes are characterized by several distinct features. They have a highly conserved 3' UTR and contain tandem repeat sequences at the 5' flank and 3' UTR which are thought to play a role in regulation of the mRNA stability. These genes have an intron immediately upstream of the initiator Met codon, which separates the site of transcription initiation from protein coding sequence. This feature is characteristic of tryptases but is unusual in other genes. The alleles of this gene exhibit an unusual amount of sequence variation, such that the alleles were once thought to represent two separate genes, beta II and beta III. Beta tryptases appear to be the main isoenzymes expressed in mast cells, whereas in basophils, alpha-tryptases predominate. Tryptases have been implicated as mediators in the pathogenesis of asthma and other allergic and inflammatory disorders. [provided by RefSeq, Jul 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Likely_benign. Variant got -2 ACMG points.
BP4
Computational evidence support a benign effect (MetaRNN=0.19787222).
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
TPSB2 | NM_024164.6 | c.261G>C | p.Arg87Ser | missense_variant | 4/6 | ENST00000606293.5 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
TPSB2 | ENST00000606293.5 | c.261G>C | p.Arg87Ser | missense_variant | 4/6 | 1 | NM_024164.6 | P2 |
Frequencies
GnomAD3 genomes AF: 0.00 AC: 125AN: 68376Hom.: 0 Cov.: 9 FAILED QC
GnomAD3 genomes
AF:
AC:
125
AN:
68376
Hom.:
Cov.:
9
FAILED QC
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.000837 AC: 56AN: 66882Hom.: 0 AF XY: 0.000960 AC XY: 33AN XY: 34392
GnomAD3 exomes
AF:
AC:
56
AN:
66882
Hom.:
AF XY:
AC XY:
33
AN XY:
34392
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.00182 AC: 2149AN: 1183002Hom.: 0 Cov.: 21 AF XY: 0.00179 AC XY: 1037AN XY: 578828
GnomAD4 exome
AF:
AC:
2149
AN:
1183002
Hom.:
Cov.:
21
AF XY:
AC XY:
1037
AN XY:
578828
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome Data not reliable, filtered out with message: AS_VQSR AF: 0.00183 AC: 125AN: 68462Hom.: 0 Cov.: 9 AF XY: 0.00197 AC XY: 62AN XY: 31490
GnomAD4 genome
Data not reliable, filtered out with message: AS_VQSR
AF:
AC:
125
AN:
68462
Hom.:
Cov.:
9
AF XY:
AC XY:
62
AN XY:
31490
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
ExAC
AF:
AC:
27
ClinVar
Significance: Uncertain significance
Submissions summary: Uncertain:1
Revision: criteria provided, single submitter
LINK: link
Submissions by phenotype
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Aug 06, 2021 | The c.261G>C (p.R87S) alteration is located in exon 4 (coding exon 3) of the TPSB2 gene. This alteration results from a G to C substitution at nucleotide position 261, causing the arginine (R) at amino acid position 87 to be replaced by a serine (S). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_addAF
Uncertain
D
BayesDel_noAF
Uncertain
CADD
Benign
DANN
Benign
Eigen
Benign
Eigen_PC
Benign
FATHMM_MKL
Benign
N
LIST_S2
Benign
T;T
M_CAP
Uncertain
D
MetaRNN
Benign
T;T
MetaSVM
Uncertain
T
MutationTaster
Benign
N
PrimateAI
Uncertain
T
Sift4G
Uncertain
T;D
Vest4
MutPred
Loss of methylation at R87 (P = 0.0264);.;
MVP
ClinPred
T
GERP RS
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at